Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) shares, rose in value, with the stock price up by 4.14% to the previous day’s close as strong demand from buyers drove the stock to $0.20.

Actively observing the price movement in the last trading, the stock closed the session at $0.19. The value of beta (5-year monthly) was 2.29. Referring to stock’s 52-week performance, its high was $3.80, and the low was $0.17. On the whole, TNXP has fluctuated by -47.64% over the past month.

With the market capitalization of Tonix Pharmaceuticals Holding Corp currently standing at about $16.77 million, investors are eagerly awaiting this quarter’s results, scheduled for May 06, 2024 – May 10, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$1.35, which is expected to increase to -$1.42 for fiscal year -$3.14 and then to about -$1.21 by fiscal year 2025. Data indicates that the EPS growth is expected to be 54.20% in 2025, while the next year’s EPS growth is forecast to be 61.50%.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Analysts have estimated the company’s revenue for the quarter at $7.5 million, with a low estimate of $7.5 million and a high estimate of $7.5 million. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $16.77 million, representing an increase of 115.90% from the revenues reported in the last year’s results.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that TNXP’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium term indicators have put the stock in the category of 100% Sell while long term indicators on average have been pointing out that it is a 100% Sell.

The stock’s technical analysis shows that the PEG ratio is about 0, with the price of TNXP currently trading nearly -38.36% and -40.38% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 25.93, while the 7-day volatility ratio is showing 30.53% which for the 30-day chart, stands at 13.27%. Furthermore, Tonix Pharmaceuticals Holding Corp (TNXP)’s beta value is 2.21, and its average true range (ATR) is 0.04.

A comparison of Tonix Pharmaceuticals Holding Corp (TNXP) with its peers suggests the former has fared considerably weaker in the market. TNXP showed an intraday change of 4.14% in last session, and over the past year, it shrunk by -94.63%%.

Data on historical trading for Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) indicates that the trading volumes over the past 10 days have averaged 5.46 million and over the past 3 months, they’ve averaged 1.91 million. According to company’s latest data on outstanding shares, there are 84.49 million shares outstanding.

Nearly 0.01% of Tonix Pharmaceuticals Holding Corp’s shares belong to company insiders and institutional investors own 19.87% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 0.97 million shares as on Mar 15, 2024, resulting in a short ratio of 0.76. According to the data, the short interest in Tonix Pharmaceuticals Holding Corp (TNXP) stood at 1.65% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 0.6 million. The stock has fallen by -50.74% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the TNXP stock heading into the next quarter.